Gilead Sciences to buy Germany's Tubulis for up to $5B
NewsBytes | April 8, 2026 1:39 AM CST
Deal includes TUB-040 and TUB-030
Gilead will pay $3.15 billion upfront and could add another $1.85 billion if certain milestones are met. This gives them access to promising drugs like TUB-040 (for ovarian and lung cancers) and TUB-030 (for multiple solid tumors).
Once the deal wraps up in the second quarter of 2026, Tubulis will become Gilead's dedicated research unit for these advanced cancer therapies.
Despite a small dip in Gilead's stock price after the news, this fits into its bigger plan to stay strong in oncology by snapping up innovative companies.
READ NEXT
-
Jailer 2: Potential Hindi Market Hit After BIG Cameo Is Shelved?
-
'Cheap, Lethal, Everywhere': Indian Army’s Drone Doctrine Signals a New Era of Warfare
-
Can Iran Charge Fees for Ships to Transit the Strait of Hormuz?
-
Salads For Weight Loss: From Breakfast To Dinner, Salad Recipes That Go With Every Meal
-
Here's How To Store Tomatoes So That They Stay Fresh Longer
